SPRO vs. AGLE, TTPH, KMDA, URGN, VNDA, INZY, ANRO, CRMD, MRSN, and NATR
Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Aeglea BioTherapeutics (AGLE), Tetraphase Pharmaceuticals (TTPH), Kamada (KMDA), UroGen Pharma (URGN), Vanda Pharmaceuticals (VNDA), Inozyme Pharma (INZY), Alto Neuroscience (ANRO), CorMedix (CRMD), Mersana Therapeutics (MRSN), and Nature's Sunshine Products (NATR). These companies are all part of the "medical" sector.
Spero Therapeutics (NASDAQ:SPRO) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
25.6% of Spero Therapeutics shares are owned by institutional investors. 4.5% of Spero Therapeutics shares are owned by company insiders. Comparatively, 6.6% of Aeglea BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Spero Therapeutics has a net margin of 21.09% compared to Aeglea BioTherapeutics' net margin of -22,195.36%. Spero Therapeutics' return on equity of 35.42% beat Aeglea BioTherapeutics' return on equity.
Spero Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 398.22%. Aeglea BioTherapeutics has a consensus price target of $17.50, suggesting a potential upside of ∞. Given Aeglea BioTherapeutics' higher probable upside, analysts clearly believe Aeglea BioTherapeutics is more favorable than Spero Therapeutics.
Spero Therapeutics has higher revenue and earnings than Aeglea BioTherapeutics. Aeglea BioTherapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aeglea BioTherapeutics received 53 more outperform votes than Spero Therapeutics when rated by MarketBeat users. However, 69.31% of users gave Spero Therapeutics an outperform vote while only 56.70% of users gave Aeglea BioTherapeutics an outperform vote.
Spero Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 2.57, suggesting that its stock price is 157% more volatile than the S&P 500.
In the previous week, Spero Therapeutics had 2 more articles in the media than Aeglea BioTherapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 0 mentions for Aeglea BioTherapeutics. Spero Therapeutics' average media sentiment score of 0.30 beat Aeglea BioTherapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.
Summary
Spero Therapeutics beats Aeglea BioTherapeutics on 13 of the 17 factors compared between the two stocks.
Get Spero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spero Therapeutics Competitors List
Related Companies and Tools
